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Acyclic nucleosides and their phosphonates possess signiﬁcantly antiviral and cytostatic activities. For
acyclic nucleosides and their phosphonates, the introduction of a chiral group to their side chain or
the absolute conﬁguration of the chiral atom could affect their biological activities obviously. Thus, the
asymmetric synthesis of chiral acyclic nucleosides and their phosphonates has received continuous
attention. The previous reports mainly focus on employing the chiral pool and chiral auxiliary methods
for the synthesis of chiral acyclic nucleosides and their phosphonates. In contrast, the asymmetric catal-
ysis methods for the synthesis of acyclic nucleosides and their phosphonates are still in the beginning.
This digest paper will serve to highlight the signiﬁcant progress that has been made in these areas.
 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Acyclic nucleosides and acyclic nucleoside phosphonates
(ANPs) possess signiﬁcant antiviral and cytostatic activities.1 In
1977–1978, Acyclovir was discovered to have extremely low
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Figure 1. Selected acyclic nucleosides and ANP approved by FDA as drugs.
M.-S. Xie et al. / Tetrahedron Letters 55 (2014) 7156–7166 7157toxicity for normal cells while have an inhibitory activity against
herpes simplex virus (HSV) which is greater than that of any hith-
erto known compound (Fig. 1).2 Subsequently, a series of acyclic
nucleosides and ANPs with diverse side chains, including Ganciclo-
vir, Penciclovir, Famciclovir, and Adefovir (Fig. 1),3 were found to
exhibit outstanding antiviral activities, ultimately resulting in the
regulatory approval of several agents for the treatment of various
antiviral infections.
Chiral acyclic nucleosides and their phosphonates usually exhi-
bit different biological activities and curative effects comparedN
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Figure 2. (a) The comparison of anti-HBV activities between achiral and chiral
ANPs; (b) Different anti-virus activities between S- and R-Cidovir; (c) Different anti-
HIV activities of S- and R-FPMPA.with the achiral ones.4 For example, Tenofovir is a chiral ANP, in
which a methyl group was introduced to the side chain of Adefovir
(Fig. 2a). Randomized clinical trials have shown that Tenofovir is
more potent than Adefovir in inhibiting replication of chronic
hepatitis B virus (HBV) in patients.5 Furthermore, the biological
activities of chiral acyclic nucleosides and their phosphonates are
signiﬁcantly affected by the absolute conﬁguration of the chiral
center. In the case of Cidofovir (Fig. 2b), the S-enantiomer shows
high antiviral activity, while its antipode, R-enantiomer, is devoid
of effect;6a In viral replication inhibition assays in humanMT4 cells
infected with SHIVDH12R, S-FPMPA has an IC50 of 1.85 lm, while the
R-enantiomer is inactive (Fig. 2c).6b Therefore, it is not surprising
that the synthesis of chiral acyclic nucleosides and their phospho-
nates has received continuous attention. In this digest paper, we
summarize the development for the synthesis of chiral acyclic
nucleosides and their phosphonates on the basis of different asym-
metric synthesis strategies.
Chiral pool strategy for the synthesis of chiral acyclic
nucleosides and their phosphonates
Up to now, enormous research effort has been contributed to
the chiral pool strategy for the synthesis of chiral acyclic nucleo-
sides and their phosphonates.7 And the following description was
based on the source of chiral starting materials.
Natural chiral starting materials
Based on natural chiral starting materials, various reactions
were used for the synthesis of chiral acyclic nucleosides and their
phosphonates, including alkylation, Mitsunobu reaction, epoxide
ring-opening reaction, silylative N-hydroxyalkylation, and the con-
struction of the nucleobase skeleton.
Alkylation
The alkylation between chiral electrophilic alkylating agents
and nucleobases is a direct method for the synthesis of chiral acy-
clic nucleosides. The alkylation reactions are classiﬁed according to
different alkylating agents including alkyl halide, methylsulfonate,
and tosylate.
Alkylation with alkyl halide. The alkylation with chiral alkyl
halides as alkylating agents to nucleobases is a direct route for the
synthesis of chiral acyclic nucleosides.8 In 1990, Panzica and
Abushanab group reported the alkylation reactions between chiral
alkyl chloride and pyrimidines to construct chiral acyclic nucleo-
side (Scheme 1).8a The chiral starting material is D-isoascorbic acid
1, which is a natural product. Subsequently, the (2R,3S)-3,4-epoxy-
1,2-O-isopropylidenebutane-1,2-diol 2 was obtained by 6 steps,8b,c
which was converted to the chiral triol 3 via 4 steps. In the pres-
ence of paraformaldehyde and hydrogen chloride gas, the chiral
alkyl chloride 4 was chloromethylated in 88% yield. After that,
the chiral alkyl chloride was coupled with the persilylated uracil
5 and thymine 6 in the presence of a catalytic amount of tetrabu-
tylammonium iodide (TBAI) to furnish the alkylated product 7 and
8 in good yields. Debenzylation of 7 and 8 provided the desired chi-
ral acyclic nucleosides 9 and 10 in excellent yields.
Alkylation with methylsulfonate. The chiral methylsulfo-
nates are also suitable alkylating agents to react with nucleobases
to construct chiral acyclic nucleosides and their phosphonates.9
In 1995, Franchetti group reported the alkylation reaction of
guanine and chiral methylsulfonate to afford chiral ANP R-PMPG
(Scheme 2).9a With S-lactic acid 11 as the chiral starting material,
the corresponding S-1,2-propanediol 12 was obtained, which was
converted to the chiral methylsulfonate 13 via 4 steps.9b In the
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7158 M.-S. Xie et al. / Tetrahedron Letters 55 (2014) 7156–7166presence of cesium carbonate as the catalyst, the alkylation reac-
tion between guanine 14 and chiral methylsulfonate 13 proceeded
smoothly, giving a 2:1 ratio of the alkylated products 15 and 16,
and the N9-alkylated product 15was isolated as the major product.
Sequential removal of the protecting groups of 15 with bromotri-
methylsilane in MeCN afforded chiral ANP R-PMPG 17 in 96% yield.
Alkylation with tosylate. Later, the chiral tosylates are also
used as the alkylating agents.10 In 2008, Zuo andNan group reported
the alkylation reaction between chiral tosylate and adenine for the
synthesis of chiral acyclic nucleoside S-DZ2002 (Scheme 3).10aWith
cheap and commercially available optical L-malic acid 18 as the
chiral starting material, the tosylate 19 was obtained via 3 steps.
Coupling of tosylate 19 with adenine 20 gave alkylated product 21
in 32% yield, which could be readily transformed to S-DZ2002 22upon spontaneous deprotection and esteriﬁcation in a methanol
solution of HCl.
Mitsunobu reaction
The Mitsunobu reaction of chiral hydroxyl compounds to
nucleobases is another method for the synthesis of chiral acyclic
nucleoside analogues.11 In 2003, Yuasa and Yokomatsu group
reported a synthetic approach to acyclic nucleotide analogues pos-
sessing a diﬂuoromethylene phosphonyl group at the side chain via
a Mitsunobu reaction (Scheme 4).11a With R-glyceraldehyde 23 as
the starting material, the protected 1,5-pentanediol derivative 24
could be afforded,11b which was transformed to chiral alcohol 25
via 3 steps. Condensation of 25 with 6-chloropurine 26 under
the Mitsunobu conditions (PPh3, DIAD, THF) afforded the acyclic
nucleoside analogue 27 in 88% yield.
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Scheme 3. Synthesis of chiral acyclic nucleoside S-DZ2002 via alkylation with tosylate.
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method to prepare chiral acyclic nucleosides with a chiral amino
side chain by the Mitsunobu reaction between L-serine and a
nucleobase (Scheme 5).11d The Mitsunobu reactions of pyrimidine
bases 28 or purine bases 29 and N-protected L-serine methyl ester
30 proceeded well, affording the corresponding chiral acyclic
nucleoside analogues 31 and 32 in moderate to good yields. Andthe target molecules could be converted to many other useful
compounds, including S-willardiine derivative 33 and S-DHPA
analogue 34.
Epoxide ring-opening reaction
The epoxide ring-opening reaction of chiral epoxides is an
efﬁcient route to construct chiral acyclic nucleosides.12 In 1994,
O OTr
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7160 M.-S. Xie et al. / Tetrahedron Letters 55 (2014) 7156–7166Vemishetti group developed a practical synthesis of S-Cidofovir
starting from R-glycidol and N-benzoylcytosine (Scheme 6).12a
First, with R-glycidol 35 (88% ee) as the chiral starting material,
the S-trityl ether 36 was obtained in 77% yield by treating with
trityl chloride. Regiospeciﬁc opening of the epoxide with
N-benzoylcytosine 37 in the presence of a catalytic amount of
sodium hydride in DMF proceeded well at 105 C, giving the
ring-opening product 38 in 82% yield. Subsequently, the chiral acy-
clic nucleoside analogue 40 was afforded by treating chiral acyclic
nucleoside 38 with diethyl tosyloxymethylphosphonate 39 in the
presence of sodium hydride. Acid catalyzed detritylation of 40with
HCl (g) afforded the corresponding alcohol, which could be
deprotected with TMSBr to give the chiral ANP 41. Finally, the
desired S-Cidofovir was afforded in 78% yield by treatment ANP
41 with concentrated ammonium hydroxide.
Silylative N-hydroxyalkylation
In 2004, Battistini and Zanardi group developed a silylative
N-hydroxyalkylation of nucleobases for the synthesis of chiralacyclic nucleosides (Scheme 7).13 With R-glyceraldehyde 23 as
the chiral startingmaterial, 2,3-O-isopropylidene-D-glyceraldehyde
42 was afforded. In the presence of TBSOTf-DIPEA as the catalyst,
the silylative coupling between 6-chloro-purine 26 and chiral alde-
hyde 42 delivered syn-conﬁgured product 43 and anti-conﬁgured
product 44 in 78% total yield with syn-adduct 43 as the major
product. Thymine and uracil were also suitable substrates in this
reaction. Additionally, the syn-adduct 43 was subjected to acidic
removal of the isopropylidene blockage (80% aqueous AcOH,
50 C), furnishing the corresponding diol 45 in good yieldwith com-
plete retention of the integrity of the TBS-protected hemiaminal
functionality.
Construction of the nucleobase skeleton
The construction of the nucleobase skeleton is another method
for the synthesis of chiral acyclic nucleosides.14 In 1967, with
R-lactic acid 46 as the chiral starting material, Schaeffer group
reported the synthesis of acyclic nucleosides through the construc-
tion of the purine skeleton (Scheme 8).14a Initially, the chiral amino
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M.-S. Xie et al. / Tetrahedron Letters 55 (2014) 7156–7166 7161alcohol 47 was obtained from R-lactic acid 46 via 3 steps.14b Con-
densation of 5-amino-4,6-dichloropyrimidine 48with chiral amino
alcohol 47 provided the intermediate pyrimidine 49. Then, cycliza-
tion of pyrimidine 49 with a mixture of triethyl orthoformate and
concentrated HCl gave the required 6-chloropurine derivative 50.
The chiral acyclic nucleoside 51 could be afforded via the reaction
with methanolic ammonia, which could be transformed to the
chiral ANP drug Tenofovir.15
Synthesis of chiral starting material via asymmetric catalysis
Apart from natural chiral starting materials, a useful strategy to
construct chiral starting materials is via asymmetric catalytic
synthesis. In 1996, Jacobsen group developed a kinetic resolution
of terminal epoxide via highly regioselective and enantioselective
ring opening with TMSN3 (Scheme 9).15 With 1 mol % of (salen)
CrN3 53 as the chiral catalyst and racemic propylene oxide 52 as
the starting material, the chiral 1-azido-2-trimethylsiloxypropane
54 was afforded in 98% yield and 97% ee, which could be trans-
formed to chiral amino alcohol 47 via deprotection and reduction
reactions. After the construction of purine skeleton, the chiral
Tenofovir could be afforded via 3 steps.O
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Scheme 9. Asymmetric catalysis to construct chiralChiral auxiliary strategy for the synthesis of chiral acyclic
nucleosides and their phosphonates
Apart from chiral pool methods, chiral auxiliary strategy is also
a useful route for the synthesis of chiral acyclic nucleosides and
their phosphonates.16 In 2005, He and Chen group reported a
highly enantioselective aza-Michael addition reaction for the syn-
thesis of chiral acyclic nucleoside (Scheme 10).16a With furfural
55 as the starting material and ()-menthol 56 as the chiral source,
the chiral Michael acceptor 5-(R)-()-menthyloxy-2(5H)-furanone
57 was afforded via 3 steps. Then, the asymmetric aza-Michael
addition of adenine 20 with chiral 2(5H)-furanone 57 proceeded
well in the presence of Et3N as base and DMSO as solvent. Subse-
quently, the chiral Michael adduct 58 was reduced by LiAlH4 in a
suspension of THF to give the enantiopure functionalized acyclic
nucleoside 59 in 82% yield with P98% ee.
Through the chiral pool and chiral auxiliary methods, various
chiral acyclic nucleosides and their phosphonates have been syn-
thesized, which are beneﬁcial to the discovery and development
of new chiral acyclic nucleoside analogue drugs. However, the
asymmetric induction strategy also has some disadvantages includ-
ing multiple steps, unavailability of chiral materials, and low totalN
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Scheme 12. Organocatalytic asymmetric aza-Michael addition for the synthesis of acyclic nucleosides.
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synthetic methods to construct chiral acyclic nucleosides and their
phosphonates. In recent years, the research has been focused on the
asymmetric catalysis strategy, which is more direct and efﬁcient for
the synthesis of chiral acyclic nucleosides and their phosphonates.
Asymmetric catalysis for the synthesis of chiral acyclic
nucleosides and their phosphonates
Asymmetric aza-Michael addition
In 2005, Jacobsen group reported the ﬁrst asymmetric
aza-Michael addition of purine derivatives to a,b-unsaturated
ketones and imides.17 With Al-salen 60 (5 mol %) as the catalyst,
the conjugate addition of 6-substituted purines 61 and various
a,b-unsaturated ketones 62 bearing aliphatic b-substituents pro-
ceeded well, affording the adducts 63 and 64 in 60–95% yields,14:1–>99:1 of N9/N7, and 90–99% ee (Scheme 11a). Furthermore,
a,b-unsaturated imides 66 were also found to be suitable sub-
strates to react with 6-substituted purines 65, although lower reac-
tion rates were observed with these electrophiles. With Al-salen 60
(5–10 mol %) catalyst, the corresponding conjugate adducts 67 and
68 were obtained in 63–93% yields, 3:1–>99:1 of N9/N7, and
91–98% ee (Scheme 11b). It is worth mentioning that extremely
high regioselectivity for N9-adducts was observed when substi-
tuted purines were examined.
In 2011, Guo and Qu group developed the ﬁrst organocatalytic
asymmetric aza-Michael addition of purine bases to a,b-unsaturated
aldehydes to afford chiral acyclic nucleosides (Scheme 12).18 With
prolinol silyl ether 69 as the organocatalyst, the enantioselective
aza-Michael addition between various purine derivatives 70 and
a,b-unsaturated aliphatic aldehydes 71 proceeded well, giving the
corresponding chiral acyclic nucleosides 72 in 82–89% yields and
89–99% ee. Unfortunately, when cinnamic aldehyde was explored,
1. 69 (10 mol%)
PhCOOH (10 mol%)
-30 oC, toluene, 24 h
2. NaBH4, MeOH
R-PMPA analogue
(EtO)2P(O)CH2OTf 75
NaH, THF, 0 oC
N
NN
N
Cl
Me
O P(OEt)2
O
NH3/CH3OH
N
NN
N
NH2
Me O P(OEt)2
O
N
N NH
N
Cl
H
O
N
NN
N
Cl
Me
OH
73
76, 55% yield, 89% ee
77, 75% yield, 89% ee
+
74, 87% yield, 89% ee
26
Scheme 13. Synthesis of R-PMPA analogue via organo-catalytic asymmetric aza-
Michael addition.
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target product could be further converted to R-PMPA analogue
(Scheme 13). Addition of 6-chloro-purine 26 to crotonaldehyde 73
in the presence of catalyst 69, followed by reduction with NaBH4
in situ, led to chiral acyclic nucleoside 74 in 87% yield and 89% ee.
Finally, treatment of chiral acyclic nucleoside 74 with phosphonate
75, followed by ammoniﬁcation of the chiral acyclic nucleoside
phosphonate analogue 76, afforded the R-PMPA analogue 77 with
full retention of the enantiomeric excess obtained initially for chiral
acyclic nucleoside 74.
In 2012, Huang and Wang group reported the organocatalytic
asymmetric aza-Michael addition of purine bases to a,b-unsatu-
rated ketones.19 In the presence of thiourea-primary amine catalyst
78, a series of purine bases 79 and a,b-unsaturated aliphaticN
N NH
N
R1
R3 R4
R2
78 (
PhC
+
O
tolu
F3C
(a)
N
N NH
N
R1
+
O
R3 R4
(b)
R1 = Cl, OBn, SMe
NHBoc, Br, H
R2 = H, Cl
R3 = Me, nPr, iPr, nBu
n-pentyl, n-hexyl
BnOCH2, Ph
R4 = Me, Et, nBu
R1 = Cl, OBn, SMe
NHBoc, Br
R3 = H, 4-Me, 4-F 
4-Cl, 3-Cl, 2-Cl
R4 = H, 4-Cl, 4-OMe
79 80
83 84
Scheme 14. Organocatalytic asymmetric aza-Michael additiketones 80 were explored, giving the adducts 81 in 67–96% yields
and 80–>99% ee (Scheme 14a). When a,b-unsaturated aromatic
enones were chosen as Michael acceptors, the optimal organo-
catalyst was changed to thiourea-primary amine catalyst 82
(Scheme 14b). And a variety of purine bases 83 and a,b-unsaturated
aromatic enones 84 were examined, affording the aza-Michael
adducts 85 in 46–63% yields and 80–94% ee. It should be noted that
the target adducts could be converted to the corresponding chiral
acyclic nucleosides through reduction.
With the successful strategy as described above, the transforma-
tions of the target adduct into non-natural nucleosidemolecule that
are similar to R-PMPA was performed (Scheme 15). Aza-Michael
addition of 6-chloro-purine 26 and a,b- unsaturated aliphatic
ketone 86 gave the adduct 87 in 88% yield and 93% ee which was
readily reduced by NaBH4, affording chiral acyclic nucleosides
syn-(2S, 4R)-88 (50% yield, 86% ee) and anti-(2R, 4R)-89. The
sequential esteriﬁcation and ammoniﬁcation of chiral acyclic
nucleoside 88 afforded the desired R-PMPA analogue 90.
Asymmetric N-allylation
In 2009, Hartwig group reported the ﬁrst highly regio- and enan-
tioselective iridium-catalyzedN-allylationsofpurines (Scheme16).20
The single component, ethylene-bound, metallacyclic iridium
catalysts 91 or 92 were generated from [Ir(COD)Cl]2 and phospho-
ramidite ligands 93 or 94. In the presence of catalyst 91 or 92, the
N-allylations between purines 95 and allylic carbonates 96 pro-
ceeded well, affording the N-allylated purines 97–100 in high yields
(up to 91% yield) with high N9/N7 selectivity (up to 96:4), high
branched-to-linear selectivity (98:2), and high enantioselectivity
(up to 98% ee). The reactions could encompass a variety of unsym-
metrical aryl, heteroaryl, and aliphatic allylic carbonates.
Subsequently, Hartwig group tried to convert chiral N-allylated
adenine derivatives to chiral acyclic nucleosides. Ozonolysis of
bis-Boc-protected adenine derivative 101, followed by reduction
of the resulting ozonide with NaBH4, formed bis-Boc-protected
S-2-(6-amino-9H-purin-9-yl)pentan-1-ol 102 in 88% yield, without
any erosion of enantiomeric purity (Scheme 17a). Hydroboration of
the monomethoxytrityl(MMTr)-protected adenine derivative 103,N
N N
N
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OOH (30 mol%)
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Scheme 15. Synthesis of R-PMPA analogue via thiourea-primary amine catalyzed asymmetric aza-Michael addition.
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Scheme 16. Asymmetric N-allylation of purine derivatives with allylic acrbonates.
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Scheme 17. Transformation of the N-allylation products to chiral acyclic
nucleosides.
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of basic hydrogen peroxide, gave MMTr-protected S-3-(6-amino-
9H-purin-9-yl)hexan-1-ol 104 in 77% yield (Scheme 17b). Thus,iridium-catalyzed allylation, followed by a combination of ozonol-
ysis and reduction or a combination of hydroboration and oxida-
tion, provided a new route to chiral acyclic nucleosides.
Asymmetric transfer hydrogenation
In 2014, Guo and Zhang group reported the ﬁrst asymmetric
transfer hydrogenation for the synthesis of chiral acyclic nucleo-
sides (Scheme 18).21 Compared with previous asymmetric methods
utilizing the nucleophilic property of N9 in purine, this strategy
introduced the ketone group to the N9 position of purine ﬁrstly.
Subsequently, the chiral acyclic nucleosides were afforded via the
asymmetric transfer hydrogenation of ketone group. With Ru-105
as the catalyst, HCOONa as the hydrogen source, the asymmetric
transfer hydrogenation of a wide range of 1-(9H-purin-9-yl)propan-
2-ones 106 proceeded well, affording the desired chiral acyclic
nucleosides 107 in 50–97% yields and 92–97% ee.
When chiral ligand 108, the enantiomer of 105, was used,
the enantioselectivity could be maintained (Scheme 19). In the
presence of Ru-108 as the catalyst, the asymmetric transfer hydro-
genation of ketone 109 worked well, giving the desired chiral
NNN
N
H3C
O
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[RuCl2(C6H6)]2 (5 mol%)
105 (6 mol%)
N
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N
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107
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R1 = Cl, I, NH2, N(Et)2, NHPh, NHBz,
N N, N O,
R2 = H, Cl, NH2
Scheme 18. Asymmetric transfer hydrogenation reaction for the synthesis of chiral acyclic nucleosides.
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Scheme 19. Synthesis of Tenofovir via asymmetric transfer hydrogenation reaction.
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esteriﬁcation with phosphonate 75 afforded the chiral acyclic
nucleoside phosphonate analogue 111, which could be transferred
to Tenofovir. It should be noted that this strategy provided a direct
and efﬁcient route to construct Tenofovir.
Miscellaneous
The ring-cleavage of ribosides is another approach for the
synthesis of chiral acyclic nucleosides.22 In 2004, Zakirova groupO
OHHO
OMe
O
N
N N
N
NH2
N
N N
N
NH2
NaIO4
4 oC, 1 h
112 113
Scheme 20. Synthesis of chiral acyclic nudeveloped a new approach for the synthesis of optically chiral acy-
clic nucleoside via the ring-cleavage of riboside (Scheme 20).22a
The diol system of riboside 112 was oxidized with an aqueous
sodium periodate solution to give the dialdehyde 113, which was
reduced to the corresponding chiral acyclic nucleoside 114 in
85% yield.
Conclusion
Up to now, an impressive number of contributions and results
have been obtained for the synthesis of chiral acyclic nucleosides
and their phosphonates. Much achievement has been obtained
via the chiral pool and chiral auxiliary strategies to afford many
new chiral acyclic nucleoside analogues. While for the asymmetric
catalysis strategy, it is still in the beginning of the synthetic devel-
opment and much work is required to develop various catalytic
asymmetric reactions for the synthesis of chiral acyclic nucleosides
and their phosphonates. Hopefully, new reactions and catalysts are
being developed to achieve higher enantioselectivity and regiose-
lectivity (such as N7 to N9 of purine). We hope that this digest
paper will provide useful information for those involved in the syn-
thesis of chiral acyclic nucleosides and their phosphonates.
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